FR2390164A1 - Anti:asthmatic methyl-xanthine compsns. - synergised with beta-sympathomimetic agents - Google Patents

Anti:asthmatic methyl-xanthine compsns. - synergised with beta-sympathomimetic agents

Info

Publication number
FR2390164A1
FR2390164A1 FR7714811A FR7714811A FR2390164A1 FR 2390164 A1 FR2390164 A1 FR 2390164A1 FR 7714811 A FR7714811 A FR 7714811A FR 7714811 A FR7714811 A FR 7714811A FR 2390164 A1 FR2390164 A1 FR 2390164A1
Authority
FR
France
Prior art keywords
beta
compsns
methyl
synergised
asthmatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7714811A
Other languages
French (fr)
Other versions
FR2390164B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR7714811A priority Critical patent/FR2390164A1/en
Publication of FR2390164A1 publication Critical patent/FR2390164A1/en
Application granted granted Critical
Publication of FR2390164B1 publication Critical patent/FR2390164B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

New antiasthmatic compsns. comprise (a) a methylxanthine (e.g. theophylline and aminophylline) and (b) a much lower concn. of >=1 beta-sympathomimetic agents salbutamol and terbutaline. Strong bronchodilator effect medicated via cyclic AMP and cyclic GMP. Intracellular cyclic AMP levels are increased by inhibition of phosphodiesterase by methyl xanthines, and by liberation of adenyl cyclase at the levels of the adrenergic bioreceptors by beta-symphathomimetic agents. Synergy is shown. A typical antiasthmatic tablet, dose 2-3 tablets daily, contained 100 mg of aminophylline, 2 mg of terbutaline sulphate and 50 mg of thiazinamium.
FR7714811A 1977-05-13 1977-05-13 Anti:asthmatic methyl-xanthine compsns. - synergised with beta-sympathomimetic agents Granted FR2390164A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7714811A FR2390164A1 (en) 1977-05-13 1977-05-13 Anti:asthmatic methyl-xanthine compsns. - synergised with beta-sympathomimetic agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7714811A FR2390164A1 (en) 1977-05-13 1977-05-13 Anti:asthmatic methyl-xanthine compsns. - synergised with beta-sympathomimetic agents

Publications (2)

Publication Number Publication Date
FR2390164A1 true FR2390164A1 (en) 1978-12-08
FR2390164B1 FR2390164B1 (en) 1980-07-18

Family

ID=9190814

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7714811A Granted FR2390164A1 (en) 1977-05-13 1977-05-13 Anti:asthmatic methyl-xanthine compsns. - synergised with beta-sympathomimetic agents

Country Status (1)

Country Link
FR (1) FR2390164A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3511236A1 (en) * 1984-04-04 1985-10-17 Aktiebolaget Draco, Lund Product with synergistic bronchodilating effect and process for its preparation
WO1988007380A1 (en) * 1987-03-25 1988-10-06 Pharmacia Ab A composition for the topical treatment of glaucoma or ocular hypertension
WO1991000730A1 (en) * 1989-07-07 1991-01-24 Dak-Laboratoriet A/S A slimming pharmaceutical composition
WO2001013953A2 (en) * 1999-08-21 2001-03-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
US6555583B2 (en) 1998-08-26 2003-04-29 Smithkline Beecham Corporation Therapies for treating pulmonary diseases
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
WO2004050067A1 (en) * 2002-11-29 2004-06-17 Cipla Limited PHARMACEUTICAL FORMULATIONS COMPRISING β-2 ADRENORECEPTOR AGONISTS AND XANTHINES

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106265567B (en) * 2016-08-30 2018-08-10 林州中农颖泰生物肽有限公司 A kind of water solubility aminophylline tablets and preparation method thereof

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3511236A1 (en) * 1984-04-04 1985-10-17 Aktiebolaget Draco, Lund Product with synergistic bronchodilating effect and process for its preparation
WO1988007380A1 (en) * 1987-03-25 1988-10-06 Pharmacia Ab A composition for the topical treatment of glaucoma or ocular hypertension
AU609807B2 (en) * 1987-03-25 1991-05-09 Pharmacia Ab A composition for the topical treatment of glaucoma or ocular hypertension
US5079253A (en) * 1987-03-25 1992-01-07 Pharmacia Ab Composition for the topical treatment of glaucoma or ocular hypertension
WO1991000730A1 (en) * 1989-07-07 1991-01-24 Dak-Laboratoriet A/S A slimming pharmaceutical composition
AU638992B2 (en) * 1989-07-07 1993-07-15 Nycomed-Dak A/S A slimming pharmaceutical composition
US5422352A (en) * 1989-07-07 1995-06-06 Nycomed Dak A/S Slimming pharmaceutical composition
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
US7056936B2 (en) 1998-02-24 2006-06-06 Altana Pharma Ag Synergistic combination
US6555583B2 (en) 1998-08-26 2003-04-29 Smithkline Beecham Corporation Therapies for treating pulmonary diseases
WO2001013953A3 (en) * 1999-08-21 2001-09-20 Byk Gulden Lomberg Chem Fab Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
WO2001013953A2 (en) * 1999-08-21 2001-03-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
EP1671651A1 (en) 1999-08-21 2006-06-21 Altana Pharma AG Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonists
NO328340B1 (en) * 1999-08-21 2010-02-01 Nycomed Gmbh Synergistic combination drug of roflumilast and salmeterol and use thereof.
EP2193808A1 (en) * 1999-08-21 2010-06-09 Nycomed GmbH Synergistic combination
CZ302882B6 (en) * 1999-08-21 2012-01-04 Nycomed Gmbh Pharmaceutical composition
WO2004050067A1 (en) * 2002-11-29 2004-06-17 Cipla Limited PHARMACEUTICAL FORMULATIONS COMPRISING β-2 ADRENORECEPTOR AGONISTS AND XANTHINES
GB2410187A (en) * 2002-11-29 2005-07-27 Cipla Ltd Pharmaceutical formulations comprising ß-2 adrenoreceptor agonists and xanthines
GB2410187B (en) * 2002-11-29 2007-06-20 Cipla Ltd Pharmaceutical formulations comprising ß-2 adrenoreceptor agonists and xanthines

Also Published As

Publication number Publication date
FR2390164B1 (en) 1980-07-18

Similar Documents

Publication Publication Date Title
JPS53134342A (en) Processing system for deposite and dispensation
LU88334I2 (en) 9- (1,3-Dihydroxy-2-propoxymethyl) guanine and its pharmaceutically acceptable salts.
Caplan In defense of agrammatism.
FR2390164A1 (en) Anti:asthmatic methyl-xanthine compsns. - synergised with beta-sympathomimetic agents
JPS5420126A (en) Pharmaceutical composition
DE2967632D1 (en) Use of a xanthine derivate in the manufacture of a medicament
JPS5386144A (en) Secret nuber altering device
EP0324328A3 (en) Use of the N-n-butyl derivative of desoxynojirimycin in the manufacture of a medicament inhibiting HIV-Virus
IE800687L (en) Xanthine derivatives
GB2014141A (en) 8???-ethyl- and 8???-methyl-4,5??? epoxymorphinan-6-one compounds
IL126795A0 (en) Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
JPS5576876A (en) Preparation of 1-(oxoalkyl)-3,7-dimethylxanthine derivatne
JPS57114512A (en) Antidia beticagent comprising (3-dimethyl-carbamoxy- phenyl)trimethyl ammonium derivative
JPS5675428A (en) Hypoglycemic agent containing procainamide hydrochloride
JPS549294A (en) 7alpha-methoxycephalosporins and process for their preparation
USD276924S (en) Bezel for a coin or token freed mechanism
JPS56115715A (en) Physiologically active agent containing (3- dimethylcarbam-oxyphenyl) trimethyl ammonium derivative
JPS5610188A (en) Xanthine derivative and its preparation
JPS57167922A (en) Psychotropic drug
USD250771S (en) Invalid's treatment basin stand
USD241397S (en)
JPS5356690A (en) Purin compund sugar derivatives and their preparation
Korotchenko et al. Formation of annular relief on the surface of a metal after exposure to a strong energy pulse
JPS53133624A (en) Highly soluble rifamplicin solid preparation
JPS56152418A (en) Hypoglycemic agent

Legal Events

Date Code Title Description
ST Notification of lapse